TG Therapeutics publishes data showing BRIUMVI reduced MS relapses by 56.7%

June 1, 2026 7:30 AM

TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found